Hemas Holdings PLC reported a resilient performance in the first quarter of FY2026, with consolidated revenue reaching Rs. 28.5 billion. Operating profit grew by 6.9% to Rs. 2.1 billion, while net earnings surged by 26.1% year-on-year to Rs. 1.2 billion. The Group attributed the growth to stronger topline performance, margin improvements, and reduced finance costs.
Under newly appointed Group CEO Ashish Chandra, Hemas reaffirmed its long-term strategic direction, with a focus on sustainable growth, overseas expansion, and the planned extension of its Thalawathugoda hospital.
The Consumer Brands segment maintained profitability despite a slight revenue dip, driven by portfolio optimisation and process efficiencies. The Healthcare sector posted robust growth of 20.2%, led by strong contributions from hospitals, pharmaceuticals, and manufacturing. Hemas Hospitals introduced Sri Lanka’s first Echosens FibroScan Expert 630 system and launched Health Plus in Wattala.
In pharmaceuticals, Hemas Pharmaceuticals Ltd. expanded its portfolio with new therapies and assumed Morison’s agency operations to sharpen manufacturing focus. The Learning sector, through Atlas, sustained market leadership, while Mobility reported improved cargo performance.
With an 83.1% YoY rise in share value and signs of macroeconomic stability, Hemas is well-positioned for its next growth phase.
